We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug.

 

We would like to inform you that we have completed the first part of the study with a single, escalating dose (FIH, SAD) (Part A), of the innovative antidiabetic drug. The project was implemented in cooperation with a Polish pharmaceutical company. The new therapy aims to reduce insulin resistance and to regulate the chronic high blood glucose level. Due to the state of the pandemic, the study was conducted in accordance with the highest sanitary standards as well as procedures related to the monitoring of the epidemic state. This approach, combined with the principles of GCP, ensured the safety and well-being of our patients. Soon we are starting the second part of the study (hello B0) with multiple, escalating dose of the new drug.

Go back

News

Christmas wishes

To all our Sponsors, partners, subcontractors and co-workers we would like to wish joyful Christmas and a Happy New Year!

Read more …

Participation in NCBiR project

As a Clinical Site we have won a tender for an innovative 1st phase project co-funded by NCBiR.

Read more …

GMP Specialist

Ms Dorota Osińska, M.Sc., Pharmacist, QP and experienced auditor, joined BioResearch and started GMP certification process.

Read more …

New Clinical Site

We have moved to our new Clinical Site, located in Kajetany, near Warsaw, where 1st phase, BQ and BA studies will be conducted.

Read more …

About Us | Services | Our Site | Partners | Smoking Risk Study | Contact Us

Early Phase Clinical Trials

2024 © Bio Research Group. All rights reserved.

 

scroll to top ▲